LYEL P&L Curve

Lyell Immunopharma, Inc. (LYEL) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $351.6M, listed on NASDAQ, employing roughly 161 people, carrying a beta of -0.07 to the broader market. Lyell Immunopharma, Inc. Led by Lynn Seely, public since 2021-06-17.

A profit/loss curve charts the theoretical gain or loss of an options position across a range of underlying prices. It helps traders visualize risk, identify breakeven points, and compare strategies before committing capital.

Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
Market Cap
$351.6M
Employees
161
IPO Date
2021-06-17
CEO
Lynn Seely
Beta
-0.07

As of Nov 13, 2026, the Lyell Immunopharma, Inc. spot price is $14.46; P&L scenarios can be constructed from the options chain. Payoff diagrams should be rebuilt from the live options chain; the preceding values are illustrative and assume a single at-the-money straddle for reference.